肠道菌群及其代谢物与非酒精性脂肪性肝病  

Intestinal Flora and Its Metabolites and Nonalcoholic Fatty Liver Disease

作　　者：刘亚萍 卢燕 张艺文 张全波[1] 汪汉 LIU Yaping;LU Yan;ZHANG Yiwen;ZHANG Quanbo;WANG Han(North Sichuan Medical College,Nanchong 637000,Sichuan,China;Department of Cardiology,The Affiliated Hospital of Southwest Jiaotong University,The Third People’s Hospital of Chengdu,Cardiovascular Disease Research Institute of Chengdu,Chengdu 610031,Sichuan,China)

机构地区：[1]川北医学院,四川南充637000 [2]西南交通大学附属医院成都市第三人民医院心内科成都市心血管病研究所,四川成都610031

出　　处：《心血管病学进展》2023年第12期1130-1134,共5页Advances in Cardiovascular Diseases

基　　金：四川省中医药管理局(2020JC0010);成都市卫健委医学科研课题(2021206)。

摘　　要：总结相关的实验研究发现,人体肠道菌群是非酒精性脂肪性肝病(NAFLD)发生发展的关键因素,除了人体肠道菌群组成的变化外,肠道菌群的代谢物也成为调节NAFLD病理过程的关键因素;有研究发现,肠道菌群的代谢物如短链脂肪酸、胆汁酸、三甲胺和乙醇等通过肠-肝轴途径影响肝脏代谢功能,从而导致疾病发生。现从NAFLD患者肠道菌群和代谢物的变化及发病机制,总结并探讨通过调节肠道菌群及其代谢物来治疗NAFLD,期望这些治疗策略会成为未来优化治疗NAFLD等代谢性肝病的有效方法。Summary of relevant experimental studies found that the human intestinal flora is a key factor in the development of non-alcoholic fatty liver disease(NAFLD).In addition to changes in the composition of human intestinal flora,the metabolites of intestinal flora also become the key factors regulating the pathological process of NAFLD.Some studies have found that metabolites of intestinal flora such as short-chain fatty acids,bile acids,trimethylamine and ethanol affect liver metabolic function through the gut-liver axis pathway,thus leading to disease.Based on the changes and pathogenesis of intestinal flora and metabolites in patients with NAFLD,this paper summarizes and discusses the treatment of NAFLD by regulating intestinal flora and metabolites,hoping that these therapeutic strategies will become effective ways to optimize the treatment of metabolic liver diseases such as NAFLD in the future.

关 键 词：肠道菌群 肠道代谢物 肠-肝轴 非酒精性脂肪性肝病 

分 类 号：R575.5[医药卫生—消化系统]